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SchizophreniaFully automated classiﬁcation algorithms have been successfully applied to diagnose a wide range of neuro-
logical and psychiatric diseases. They are sufﬁciently robust to handle data from different scanners for many
applications and in speciﬁc cases outperform radiologists. This article provides an overview of current appli-
cations taking structural imaging in Alzheimer's disease and schizophrenia as well as functional imaging to
diagnose depression as examples. In this context, we also report studies aiming to predict the future course
of the disease and the response to treatment for the individual. This has obvious clinical relevance but is also
important for the design of treatment studies that may aim to include a cohort with a predicted fast disease
progression to be more sensitive to detect treatment effects.
In the second part, we present our own opinions on i) the role these classiﬁcation methods can play in the
clinical setting; ii) where their limitations are at the moment and iii) how those can be overcome. Speciﬁcally,
we discuss strategies to deal with disease heterogeneity, diagnostic uncertainties, a probabilistic framework
for classiﬁcation and multi-class classiﬁcation approaches.
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 license.Introduction
Multivariate pattern recognition methods are becoming increas-
ingly popular in the ﬁeld of cognitive neuroscience, speciﬁcally their
application for the interpretation of brain images. They are hotly de-
bated in the context of mind reading, lie detection and free will
(Aharoni et al., 2008; Bles and Haynes, 2008; Soon et al., 2008). In
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from functional magnetic resonance imaging (fMRI) data (Friston et
al., 2008). The second major application has been to provide clinical
diagnosis and prognosis in patients with diseases such as Alzheimer's
disease (AD). While cognitive scientists are mostly interested in rele-
vant brain regions and potentially their local architecture; high diag-
nostic accuracy is of greatest importance when using these methods
for clinical purposes. These classiﬁcation methods also rely on recog-
nition models that have been deﬁned by training data. The critical
task is the correct labelling of new data while inference on the
model parameters is of a lesser interest (Friston et al., 2008).
Recent developments with a clinical context include the applica-
tion to structural neuroimaging data for the purpose of diagnosing in-
dividual patients (Davatzikos et al., 2008a,b, 2009; Duchesnay et al.,
2007; Fan et al., 2006, 2007; Klöppel et al., 2008b, 2009a;
Koutsouleris et al., 2009; Lerch et al., 2008; Teipel et al., 2007a,b;
Vemuri et al., 2008a,b). Classiﬁers are sufﬁciently sensitive to sepa-
rate patients with AD or mild cognitive impairment (MCI) (Petersen
et al., 2001) from cognitively normal persons (Davatzikos et al.,
2008a,b). In other applications, they identiﬁed those cognitively nor-
mal subjects who will convert to MCI in the future (Davatzikos et al.,
2009). Although most applications have been applied to T1-weighted
data, these methods perform well on other imaging modalities such
as positron emission tomography (PET) (Chen et al., 2011; Dukart
et al., 2011; Habeck et al., 2008; Walhovd et al., 2010; Zhang et al.,
2011) and functional MRI (fMRI) (Costafreda et al., 2009b; Fu et al.,
2008; Hahn et al., 2011; Marquand et al., 2008; Nouretdinov et al.,
2011). Many of these studies provide evidence that classiﬁers can
be applied clinically to predict the course of disease in individuals
and possibly even the combination of symptoms in the individual
patient (Klöppel, 2009). This information is not only highly relevant
to patient management but also very important for designing treat-
ment trials. Pre-selecting subjects with a predicted rapid decline
will allow for shorter and less expensive trials as treatment related
changes can be identiﬁed more easily.
Since there is a number of review articles on pattern recognition
methods (Muller et al., 2001; Rätsch, 2004; Schölkopf and Smola,
2001; Shawe-Taylor and Cristianini, 2004; Vapnik, 1998) and several
deal with the speciﬁc application to neuroimaging (Bles and Haynes,
2008; Lemm et al., 2011), the main focus of this review will be on the
current clinical applications of pattern recognition methods and the
steps necessary to integrate them in the clinical routine. To keep
this review accessible to readers unfamiliar with classiﬁcation
methods in neuroscience, we begin with a brief outline of the main el-
ements of the analysis pipeline and present an example of a pipeline
to discriminate AD from healthy controls. Next, we discuss studies
that relied on classiﬁcation methods for diagnostic purposes and the
diagnostic accuracy achievable. In the remainder of this text we dis-
cuss current challenges and how these could be overcome.
Basic elements of a classiﬁcation pipeline
The analysis pipelines used for generating MRI-based recognition
models for an individualised patient diagnosis vary greatly but often
include the following four steps:
1) Training data set: The goal is to acquire a sufﬁcient number of
training data sets from individual subjects with well-characterised
clinical properties (e.g. clinical diagnosis, pathological measures),
which can be used as the gold standard for the classiﬁcation prob-
lem at hand. Since we typically use supervised pattern recognition
methods, training data along with the gold standard forms the li-
brary for learning disease-speciﬁc properties (i.e. patterns) to clas-
sify new incoming patients. The training data set has to be large
enough to reliably express the disease effect against the “noise” of
inter-subject variability.2) Feature extraction from raw data and dimensionality reduction:
The input data (e.g. the anatomical or functional characteristics
of the disease process) have to be useful for classiﬁcation or in
other words, they need to be meaningful in the context of the dis-
ease and comparable (stable) across subjects. The input data can
be as coarse as the total intracranial volume (TIV) or as ﬁne as
the amount of grey matter in a very small anatomical region, i.e.
a voxel. Since neuroimaging data can have 106 or more dimen-
sions depending on resolution and scanned volume, often but
not always the numbers of input measures are reduced using var-
ious dimensionality reduction methods. Irrespective of the speciﬁc
type of algorithms, all dimensionality reduction methods aim at
generating a compact set of discriminative “features” that can be
used for training the classiﬁcation model instead of the original
input data.
A popular dimensionality reduction method is principle component
analysis (PCA), but many others exist (Guyon and Elisseeff, 2003). This
approach is effective in improving signal-to-noise ratio as it extracts
potentially relevant information bymeans of an alternative representa-
tion of the data that is based on the covariance matrix. However, PCA is
usually applied to the entire brain and therefore it produces features
that provide discriminative information only at the whole-brain level.
Thus, one major drawback of this dimensionality reduction method is
that it misses highly localized pathological information characteristic
for certain neurodegenerative disorders (e.g. Huntington's disease,
etc.). A second limitation is that PCA is agnostic with respect to the
classiﬁcation problem at hand, meaning that the algorithm will
produce features that e.g. are age-associated if age effects account for
most of the variance in the data.
In contrast, another strategy that has been employed to decrease
dimensionality is the selection of a predeﬁned set of features (e.g. an-
atomic regions) for classiﬁcation using some prior knowledge, e.g.
medial temporal lobe or hippocampus pathology in AD. Although
very powerful, this approach requires an established and validated
model describing the functional neuroanatomy of the underlying dis-
ease processes. This may be the case for certain neurological conditions
(e.g. stroke, Alzheimer's or Huntington's disease), but in psychiatric
disorders, like schizophrenia and depression, the pathophysiological
processes are still far less understood. Furthermore, the complex and
often heterogeneous clinical phenotypes of these diseases suggest
that the underlying neurobiological substrate is also equally complex
(see e.g. reviews by Honea et al. (2005) and Koolschijn et al. (2009)),
potentially spanning multiple brain systems beyond predeﬁned neuro-
anatomical boundaries. Therefore, the plan to overcome “the curse of
dimensionality” by selecting a small set of brain regions may result in
a signiﬁcant loss of discriminative information. Taken together, these
two different approaches illustrate that no universal strategy of feature
selection might exist, but instead that the optimal approach has to be
determined according to the very speciﬁc diagnostic/predictive task at
hand.
A third, recently proposed approach (Gilad-Bachrach et al., 2004;
Navot et al., 2006) may provide an intermediate solution to the
above-mentioned feature selection problem as it selects patterns of
discriminative voxels by evaluating the geometric distance in feature
space they induce between different groups in the training data. This
margin-based feature selection framework may be capable of provid-
ing both global as well as local discriminative information, thus
reducing the effect of noisy, unreliable or irrelevant voxels, while
avoiding the drawback of the aforementioned dimensionality reduction
strategies.
3) Model training and optimization: The classiﬁer uses the training
data and the known labels to learn a rule to separate the classes.
In this step, a supervised algorithm is selected (e.g. linear discrim-
inant analysis, support vector machine (SVM), neural networks,
Gaussian processes etc.) and the parameters of the model are
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the basis of the training data set. Cross-validation is a widely
used approach to tune the parameters of the model. N-fold
cross-validation involves randomly dividing the entire data set
into N subgroups and then training the algorithmwith speciﬁc pa-
rameters on N-1 subgroups and testing on the left-out subgroup.
This process is repeated by leaving each of the sub-groups out
one at a time and estimating the average error over all the runs.
The model (or the parameters) that gives the best accuracy is
picked as the ﬁnal model. If the number of sub-groups is equal
to the number of samples, it is called leave-one out cross-
validation since each sample is left out once and used as the test
sample.
Another important aspect to consider during the model optimiza-
tion is the operating point. By default, the operating point of any
classiﬁcation algorithm is set to maximize the accuracy but depending
upon the problem can be set to maximize sensitivity or speciﬁcity.
For clinical applications, the operating point can be set to give higher
sensitivity if the algorithm results are used for screening a population
or high speciﬁcity if the results are used to identify candidates for high
risk therapeutics.
4) Application to test data: The ﬁnal step is to apply the learned rule
to new data that have been pre-processed in the same way as the
training data set. Testing the model on a new independent test
data set that was not used for training is the best approach to
test the generalisability and performance of the developed model.
In caseswhere an independent test set is not available due to limited
samples for testing and training one can use the cross-validation
framework described above to estimate the performance of the
model.
Fig. 1 shows artiﬁcial data that can be separated into two groups
without error by using information from two dimensions. A univari-
ate classiﬁer taking only one dimension (e.g. x-axis in Fig. 1) into
account could not accurately separate the classes. In an actual applica-
tion the amount of GM at each anatomical position is the meaningful
and comparable feature and there could easily be several thousand
dimensions instead of just two as shown in Fig. 1.
It is important to note that there are several parameters that
can inﬂuence the performance of classiﬁers. Several studies haveFig. 1. Concept of multivariate classiﬁcation in two dimensions.studied the effect of pre-processing on the classiﬁcation performance
(Cuingnet et al., 2011; Franke et al., 2010); compared different classi-
ﬁcation algorithms for structural (Chen and Herskovits, 2010; Plant
et al., 2010) and functional (Sato et al., 2009) imaging data as well as
compared the performance of anatomical versus statistical regions
for separating two classes (Pelaez-Coca et al., 2011). It is unlikely that
the same pre-processing pipeline and classiﬁcation method performs
best in all scenarios.
Current applications
We start by discussing structural magnetic resonance imaging
(sMRI) and AD. This neurodegenerative disease has a clear patholog-
ical correlate related to loss of neurons and synapses particularly in
the medial temporal lobe. Applications to psychiatric diseases are
potentially more challenging since they present with more heteroge-
neous clinical phenotypes. To this end, we report sMRI-based classiﬁca-
tion studies in schizophrenia.We conclude this section by summarising
fMRI studies useful to diagnose depression and report ﬁrst evidence
for a successful prediction of treatment response using classiﬁcation
methods.
Dementia
As listed in the introduction, many studies have applied pattern
recognition methods to diagnose individual patients with dementia.
With only two potential diagnoses available such as AD (the most
common form of dementia) and cognitively normal subjects, classiﬁers
have been shown to outperform radiologists (Klöppel et al., 2008a) and
to capture the neurodegenerative pathology better than hippocampal
volumes which have been traditionally used (Vemuri et al., 2008b).
Since there are signiﬁcant pathological changes before clinical symp-
toms appear in AD, predicting conversion from MCI to AD (i.e. early
diagnosis of AD) is one of the key areas of biomarker research in
this ﬁeld. Visual qualitative estimates of medial temporal atrophy
which are performed routinely, predict the progression of MCI to
dementia with a sensitivity of 68% and speciﬁcity of 69% (DeCarli
et al., 2007; Korf et al., 2004). This is outperformed by multivariate
classiﬁcation methods based on sMRI that have accuracy of 80%
(sensitivity 67; speciﬁcity 93%) in identifying MCIs who later convert
to AD (Teipel et al., 2007b). There are also recent studies showing that
pattern recognition method based MRI scores predict disease pro-
gression better when compared to CSF biomarkers (Davatzikos
et al., 2011; Vemuri et al., 2009a) and closely correlate with cognitive
performance in subjects (Stonnington et al., 2010; Vemuri et al., 2009b).
While MRI-based methods might not show best performance for all
applications, the above mentioned studies indicate that the relative
ease of data acquisition and applying automated diagnosis methods
and the non-invasive nature ofMRImake it a useful diagnosticmeasure.
The need for fully automated diagnostic tools in AD has just in-
creased signiﬁcantly with the release of new diagnostic criteria for
AD. Recently both Dubois et al. (2010) as well as the Alzheimer's As-
sociation and National Institute on Aging published (Albert et al.,
2011; Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011)
recommendations for updated diagnostic criteria that include AD
biomarkers in the diagnostic scheme. Evidence of medial temporal
atrophy on structural MRI was one of the major biomarkers included
in these recommendations.
Schizophrenia
In contrast to the promising results in the dementia ﬁeld, potential
MRI-based biomarkers of schizophrenia have been described only by
few studies despite the large body of well replicated evidence sup-
porting structural and functional brain alterations in this patient
population (Honea et al., 2005). The ﬁrst study to use advanced pattern
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was published by Davatzikos et al. (2005) based on a population of 69
schizophrenic patients (SCZ) and 79 healthy controls (HC). The authors
reported an accuracy over 80.0% for separating either male or female
SCZ patients fromHC. Similarly, Kawasaki et al. (2007) observed a clas-
siﬁcation accuracy of 80% when applying a partial least squares model
trained on a group of 30 SCZ patients and 30 HC to an independent
test population (n=16 SCZ, n=16 HC). Recently, Ardekani and col-
leagues (Ardekani et al., 2010) used diffusivity and fractional anisotropy
data of 25 SCZ and 25 HC to train a linear discriminant analysis (LDA)
classiﬁer. They found that the developed LDAmodelwas capable of cor-
rectly classifying 98% of the cases (96% sensitivity, 100% speciﬁcity) in a
test population of 25 SCZ and 25 HC.
Although these classiﬁcation results provide important leads, fur-
ther open questions related to the clinical applicability of diagnostic
MRI-based biomarkers have to be resolved. First, the examined sam-
ple sizes are still small and therefore they may not fully represent
the broad cross-sectional spectrum of different disease phenotypes
subsumed under and possibly coerced into the diagnostic construct
of “schizophrenia” (Tsuang et al., 1990). The additional and interact-
ing effects of disease duration and medication (Ho et al., 2011) may
further impact the neurobiological substrate in a complex and still
poorly understood way, thus adding a longitudinal dimension to the
heterogeneity of this patient population. Therefore, the development
of predictive methods in high-risk, prodromal or ﬁrst-episode popu-
lations may surmount these conceptual pitfalls, as demonstrated re-
cently (Koutsouleris et al., 2009; Sun et al., 2009). Nevertheless, the
neurobiological boundaries between schizophrenia, schizoaffective
and bipolar disorder remain unclear with respect to recent genetic
and structural imaging ﬁndings, which suggested a considerable
degree of pathophysiological overlap between these nosological
constructs.
Taken together, it remains unclear whether MRI-based pattern
recognition methods trained to dichotomize between HC and SCZ
would achieve the level of sensitivity and speciﬁcity needed to be in-
tegrated into clinical real-world scenarios. In case the cross-sectional
and longitudinal clinical heterogeneity of the disease construct is sub-
served by a similarly complex neurobiological substrate, it is highly
likely that such classiﬁers would fail to provide generalisable diagnos-
tic performance. In this context, recently proposed semi-supervised
machine learning algorithms (Filipovych et al., 2010) may provide
an alternative to fully supervised machine learning methods in that
they are capable of deconstructing the heterogeneity of schizophrenia
by modelling the hidden neurobiological clustering within this pa-
tient population. In addition, the methodological shift from single
predictive models to ensembles of classiﬁers may produce more robust
and generalisable diagnostic biomarkers because ensemble methods
have been shown to reduce the risk of unfortunate selections of poorly
performing single classiﬁers by averaging the diagnostic decisions of
numerous predictive models (Koutsouleris et al., 2010, in press;
Polikar, 2006).
Depression
To date the diagnosis of depression is based on behavioural symp-
toms and course of illness and treatment guidelines are based on
clinical empirical evidence and expert consensus. However the in-
terest in neurobiological markers of depression has grown substan-
tially in recent years. Studies have shown that a combination of fMRI
and pattern recognition techniques can accurately discriminate de-
pressed subjects from healthy controls (Fu et al., 2008; Hahn et al.,
2011; Marquand et al., 2008; Nouretdinov et al., 2011) and predict
treatment response (Costafreda et al., 2009a,b).
As depression is associated with negative bias and impairments in
interpersonal relationships (Fu et al., 2004) it seems advantageous to
build up a diagnostic system for depression based on fMRI patterns ofbrain activation in response to emotional and affective processing.
Fu et al. (Fu et al., 2008) have shown that pattern of brain activity
during sad facial processing when analyzed with SVM correctly
classiﬁed up to 84% of patients (sensitivity) and 89% of controls sub-
jects (speciﬁcity). As expected, Marquand et al. (2008) obtained lower
diagnostic accuracy using pattern of brain activation to verbal working
memory. They found that prediction accuracy based on fMRI data
during an n-back task was highest (68% accuracy) in the 2-back
condition. Hahn et al. (2011) showed that integrating predictions
based on brain activation associated with emotional and affective
processing substantially increased the accuracy to discriminate a
heterogeneous group of depressed patients (i.e. patients who were
on a variety of medications and with varying degrees of depressive
symptoms) from healthy controls. Their best single classiﬁer achieved
an accuracy of 72% while the decision tree algorithm integrating the
prediction of single classiﬁers leads to 83% accuracy (80% sensitivity
and 87% speciﬁcity).
Attempting to predict treatment response, Costafreda et al. showed
that structuralMRI features are predictive of an individual patient's clin-
ical response to antidepressant medication with an accuracy of 89%,
while fMRI responses showed the greatest predictive potential for cog-
nitive behaviour therapy with an accuracy of 79% (Costafreda et al.,
2009a,b).
Mourão-Miranda et al. (2011) applied one-class SVM approach to
investigate if patterns of fMRI response to sad facial expressions in
depressed patients would be classiﬁed as outliers in relation to pat-
terns of healthy control subjects. They found a signiﬁcant correlation
between the OC-SVM predictions and the patients' Hamilton Rating
Scale for Depression (HRSD), i.e. the more depressed the patients
were the more of an outlier they were. In addition the OC-SVM split
the patient groups into two subgroups whose membership were as-
sociated with future response to treatment, i.e. among the patients
classiﬁed as outliers 70% did not respond to treatment and among
those classiﬁed as non-outliers 89% responded to treatment.
As a methodological contribution, Nouretdinov et al. (2011)
applied transductive conformal predictor (TCP) to structural and
functional MRI data to investigate diagnostic and prognostic predic-
tion in depression and compute conﬁdence for each prediction. Their
approach was as accurate as those obtained with previous results
using SVM.Discussion
Potential clinical applications
The studies presented here show encouraging results and have a
number of implications that suggest a general adoption of computer-
assisted methods for MRI scan-based diagnosis should be seriously
considered. The most important of these implications are that these
methods can a) improve diagnosis in places where trained neuroradi-
ologists or cognitive neurologists are scarce; b) increase the speed
of diagnosis without compromising accuracy by eschewing lengthy
specialist investigations; and c) aid the recruitment of clinically homo-
geneous patient populations for pharmacological trials, d) reduce sub-
jectivity in diagnostic assessment that is inherent in the traditional
mode of radiological practise which is focused on providing a written
narrative report based on subjective diagnostic impression. The clinical
application of these techniques is largely dependent on the disease
under study. For the case of dementia, primary care and local referral
play an important role in the diagnosis of a disease as common as AD.
In this context, computerised methods may be especially helpful for
screening purposes. Identifying those with subthreshold psychotic
symptoms who will soon develop schizophrenia is clinically highly rel-
evant to justify medication with often signiﬁcant side-effects. For all
scenarios, including depression, predicting future disease course or
Fig. 2. Potential setting for a clinical application. Imaging data is collected in a specialized imaging center (upper panel) and gold-standard diagnosis is established using labor-intesive
methods such as post-mortem histological examination as gold-standard. Classiﬁer is trained on the imaging data using the gold-standard labels. Trained algorithm is distributed
electronically to another clinic (lower panel) and applied to patient data.
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and relatives but also to avoid unnecessary medication.
The basic implementation of how these methods can be applied
clinically is shown in Fig. 2. It includes a training dataset acquired at
a highly specialized imaging centre (shown by the top row in Fig. 2)
which has access to both a large training data set as well as a gold
standard measure for classiﬁcation. This information will be used to
develop diagnostic algorithms and be made available at primary re-
ferral centres. When the radiologist sees a new patient's scan there,
he/she would be able to use the library/diagnostic algorithm made
available to make an informed decision about underlying disease in
the patient (shown in the bottom panel of Fig. 2).
Necessary future developments and directions
Multi-class classiﬁcation methods for clinical applications
While two-class classiﬁcation problems have typically been devel-
oped, one of the key issues in the clinic is the differential diagnosis
of patients across several disease subtypes. For example in neurode-
generative dementia, there are at least three common pathologies
underlying dementia subtypes — AD, Lewy body disease and fronto-
temporal lobar degeneration.
Such multi-class problems can be solved either by applying pair-
wise classiﬁers where there is a two-class algorithm to separate
pairs of disease subtypes or by applying a one-against all classiﬁer
where a two-class algorithm is used to separate each subtype from
all others. While the approach described above works well in most
multi-class problems, combining information from several indepen-
dent two-class classiﬁers represents ambiguity when providing a
single diagnosis for a patient especially in the presence of mixed
diseases. A suggested alternative approach for this problem is to apply
simultaneous clustering of subjects solely based on their image fea-
tures and using a simpliﬁed mixture model to label subjects as be-
longing to speciﬁc disease subtype clusters (Vemuri et al., 2011).
More methods need to be developed and/or applied for the problem
of differential diagnosis of disease subtypes.
Development of robust classiﬁcation methods
A general application to the clinical setting will lead to suboptimal
conditions in terms of data acquisition. This could start with some-
what outdated hardware and scanning sequences as well as limited
equipment for stimulus presentation and response recording for
fMRI activation studies. It also has time constraints, partly becausesubjects are often unable to remain still for prolonged intervals and
partly because longer scan time is more expensive. A related problem
is the presence of additional brain pathology unrelated to the clinical
question. This will be particularly relevant when classiﬁers are ap-
plied to the elderly where small stroke lesions or vascular pathology
poses a challenge to the classiﬁers. So far, studies have excluded
such subjects from the analyses (also see section on outlier rejection)
and we are not aware of any studies that have formally addressed this
problem.
Addressing disease heterogeneity
Another important problem comes from a substantial heterogene-
ity that exists between patients. While studies in cognitive neuroim-
aging recruit subjects similar in age or education and usually include
those with any type of brain pathology, this is in stark contrast to the
clinical setting where subjects may have several types of pathology
and differ in disease stage and demographic variables. An example
for this is dementia where mixed dementia cases constitute about
40% of all dementia cases.
Large training data sets increase classiﬁcation accuracy (Franke
et al., 2010; Klöppel et al., 2009b) and may be able to reduce problems
with disease heterogeneity as they can integrate the whole spectrum of
clinical and pathological manifestations. Standardized data sharing has
started for structural imaging (Marcus et al., 2007; Mueller et al., 2005)
but it is still rare for fMRI data (Biswal et al., 2010). This is partly due to
the higher heterogeneity of stimuli and the dependence on e.g. instruc-
tions for research on higher cognitive functions.
Outlier detection approaches: This approach can be applied to situ-
ations where one is interested in accessing deviations from a speciﬁc
class or population, e.g. treating patient classiﬁcation as an outlier
detection problem (Mourão-Miranda et al., 2011). This option may
also be suitable when the current case to be classiﬁed differs substan-
tially from those in the training set. Classiﬁcation of such cases will be
unreliable and they could be rejected already in the pre-processing
stage by comparing them to each training group. Another interesting
possibility may also be the rejection of outliers in the training set
which could become more homogeneous and representative of each
class.
Dealing with diagnostic uncertainties
The need for large datasets necessarily often entails the need to in-
clude cases with lower diagnostic certainty. Besides, the deﬁnition of
a gold standard may often be a matter of debate. Consequently, this
462 S. Klöppel et al. / NeuroImage 61 (2012) 457–463uncertainty should be returned to the clinician who is making the ac-
tual diagnoses. What is needed is therefore a framework that inte-
grates uncertainties that start with the training data and continue
through the classiﬁcation process.
Probabilistic classiﬁcation approaches, such as Gaussian Process
Classiﬁers (Rasmussen and Williams, 2006), have the advantage of
furnishing predictive probabilities for the test examples (i.e. they en-
code a measure of predictive conﬁdence, which can separate exam-
ples that are conﬁdently classiﬁed from the more ambiguous ones).
This approach has been recently been applied to classify whole-brain
pattern of brain activity in response to thermal pain (Marquand et al.,
2010) and to classify depressed patients vs. healthy controls (Hahn
et al., 2011). In addition approaches such as the Sparse Multinomial
Logistic Regression (Krishnapuram and Carin, 2005; Ryali et al., 2010)
can be used to furnish predictive probabilities in multi-class problems.
Alternatively, measures of predictive conﬁdence can also be obtained
from classiﬁcation algorithms that do not readily produce probability
outputs (e.g. SVM) using ensemble-based learning approaches. These
ensemble strategies generate probability outputs for new unseen sub-
jects by combining the outputs of numerous classiﬁcation models
according to e.g. majority voting, boosting or mixture of expert
schemes (Polikar, 2006).
A complementary strategy to deal with diagnostic uncertainties is
the use of semi-supervised classiﬁcation methods. The assumption so
far has been that the clinical or pathological diagnosis which is con-
sidered as the gold standard for developing the classiﬁer is available
for all subjects. This is far from reality in the clinic where mild
forms of the disease are difﬁcult to classify into disease or normal
groups. Therefore there may be two groups of patients available —
labelled where the gold standard is available and unlabelled where
the gold standard is unavailable or unreliable.
One might consider using only the labelled datasets for training
the classiﬁer but this will not perform well in the cases where there
is a small number of labelled data sets or the actual distribution of
the disease features is more complex that the distribution of the la-
belled features. In such cases, semi-supervised methods are often
used (Vapnik, 1998). These methods have recently been shown to
be efﬁcient in using all the unlabelled as well as labelled data sets to
develop methods with high generalisability and accuracy (Filipovych
et al., 2010).References
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